Table 4.
Clinical characteristics, grouped by AFP progression (AFP increase by ⩾20%).
| Characteristic | Not evaluable (n = 51) | AFP non-progression (n = 82) | AFP progression (n = 42) | p Value |
|---|---|---|---|---|
| Male | 45 (88.2) | 72 (87.8) | 37 (88.1) | 0.997 |
| Ethnicity | ||||
| White | 32 (62.7) | 57 (69.5) | 20 (47.6) | |
| Asian | 13 (25.5) | 14 (17.1) | 18 (42.9) | |
| Black | 3 (5.9) | 8 (9.8) | 4 (9.5) | |
| Latinx | 1 (2.0) | 1 (1.2) | 0 (0.0) | |
| American Indian or Alaska Native | 2 (3.9) | 2 (2.4) | 0 (0.0) | |
| Viral status | ||||
| Active/prior HBV infection | 27 (52.9) | 30 (36.6) | 24 (57.1) | 0.151 |
| Active/prior HCV infection | 25 (49.0) | 41 (50.0) | 17 (40.5) | 0.537 |
| Non-viral | 17 (33.3) | 29 (35.4) | 12 (28.6) | 0.463 |
| Child-Pugh class | 0.942 | |||
| A | 43 (86.0) | 72 (87.8) | 37 (88.1) | |
| B | 7 (14.0) | 10 (12.2) | 5 (11.9) | |
| BCLC stage | 0.199 | |||
| A | 1 (2.0) | 3 (3.7) | 0 (0.0) | |
| B | 8 (15.7) | 4 (4.9) | 4 (9.5) | |
| C | 42 (82.4) | 75 (91.5) | 38 (90.5) | |
| Baseline AFP | 6 [4, 13] | 694 [94, 7065] | 988 [187, 10,667] | <0.001 |
| Best AFP change within 3 months (using lowest available on-treatment AFP value) | N/A | −48.1% [−13.8%, −75.0%] | +90.2% [+44.1%, +161.0%] | <0.001 |
| SOR monotherapy | 26 (51.0) | 37 (45.1) | 25 (59.5) | 0.314 |
| Other drug | 0.594 | |||
| Chemotherapy | 7 (13.7) | 14 (17.1) | 7 (16.7) | |
| Targeted therapy | 17 (33.3) | 30 (36.6) | 9 (21.4) | |
| SOR discontinued | 50 (98.0) | 79 (96.3) | 41 (97.6) | 0.830 |
| Immunotherapy after SOR | 14 (27.5) | 21 (25.6) | 11 (26.2) | 0.882 |
| Death | 46 (90.2) | 55 (67.1) | 35 (83.3) | 0.012 |
Data are median (IQR) or n (%).
APE, alpha-fetoprotein; CPI, checkpoint inhibitor; IQR, interquartile range; SOR, sorafenib; TOT, time on treatment.